New England Research & Management’s DexCom DXCM Stock Holding History

New England Research & Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,915	Closed	-$444K	–	164
2024 Q2	$444K	Buy	+3,915	New	+$495K	0.21%	133
2024 Q1	–	Sell	-2,950	Closed	-$366K	–	163
2023 Q4	$366K	Buy	+2,950	New	+$301K	0.19%	128
2022 Q4	–	Sell	-2,590	Closed	-$209K	–	160
2022 Q3	$209K	Buy	+2,590	New	+$219K	0.13%	150
2022 Q2	–	Sell	-1,840	Closed	-$235K	–	161
2022 Q1	$235K	Hold	1,840	–	–	0.12%	144
2021 Q4	$247K	Hold	1,840	–	–	0.12%	165
2021 Q3	$252K	Sell	1,840 -3,260	-64%	-$411K	0.13%	156
2021 Q2	$544K	Sell	5,100 -100	-2%	-$9.6K	0.28%	112
2021 Q1	$467K	Hold	5,200	–	–	0.26%	106
2020 Q4	$481K	Buy	+5,200	New	+$464K	0.3%	103
2019 Q2	–	Sell	-10,200	Closed	-$304K	–	169
2019 Q1	$304K	Buy	+10,200	New	+$358K	0.21%	129

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

New England Research & Management's DXCM Position: Q3 2024 in Review

New England Research & Management sold out of DexCom (DXCM) in Q3 2024, closing a stake of 3,915 shares — an estimated $444K sold.

New England Research & Management first reported a position in DXCM in Q1 2019 and held it in 10 quarters. The position peaked at $544K in Q2 2021. 890 funds tracked by Wall St. Rank hold DXCM as of Q3 2024.

New England Research & Management reported no remaining DexCom position as of Q3 2024 after selling out during the quarter.
New England Research & Management sold 3,915 DexCom shares in Q3 2024, an estimated $444K.
New England Research & Management first reported a position in DexCom in Q1 2019 and held it in 10 quarters.
New England Research & Management's DexCom position peaked at $544K in Q2 2021.
890 funds tracked by Wall St. Rank held DexCom as of Q3 2024.

Based on New England Research & Management's 13F filing for Q3 2024, filed 7 Oct 2024.